Teva Pharmaceutical Industries Ltd. Financial Results
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) recently announced its third-quarter financial results, reporting impressive total revenue of $4.48 billion. This figure surpassed analysts' estimates of $4.35 billion, showcasing the company's strong performance in the market.
Key Revenue Insights and Growth Drivers
Year-over-year, Teva's revenues grew by 3% in U.S. dollars, or 1% when considering local currency adjustments. The significant driver of this growth continues to be the company's key brands, which saw a notable 33% increase in revenues, reaching $830 million.
Sales Performance of Leading Products
The sales figures for specific drugs illustrate this success. For instance, Austedo, a drug used to treat Huntington's disease, reported remarkable sales growth of 38%, climbing to $618 million. Based on this momentum, the revenue outlook for Austedo has been adjusted to boost expectations to between $2.05 billion and $2.15 billion for the fiscal year.
Ajovy, a medication targeting migraines, achieved sales of $168 million, reflecting a 19% increase in local currency year-over-year. This drug's performance supports a reaffirmed revenue outlook of $630 million to $640 million for 2025.
Growth in New Drug Revenues
Additionally, Uzedy, used in treating schizophrenia, reported revenues of $43 million, marking a 24% increase. This drug's revenue outlook remains positive, with expectations set between $190 million and $200 million for 2025. Long-term expectations for the long-acting injectable schizophrenia franchise are projected to reach between $1.5 billion and $2 billion, inclusive of olanzapine long-acting injections.
Global Generics and Overall Performance
Teva's global generics segment has also seen an uplift of 2% compared to the previous year in the third quarter. The adjusted earnings for the company were reported at 78 cents per share, exceeding the consensus expectation of 66 cents, an increase from 69 cents reported last year.
Outlook for 2025
Looking ahead, Teva Pharmaceutical Industries has refined its fiscal year 2025 adjusted earnings guidance from a range of $2.50 - $2.60 per share to $2.55 - $2.65. This is slightly higher than the market consensus of $2.58.
Regarding sales, the company narrowed its 2025 forecast from $16.8 billion-$17.2 billion to between $16.8 billion and $17 billion, compared with an average consensus of $16.89 billion.
Market Positioning and Stock Performance
Teva's CEO has indicated that the company is well-prepared for potential U.S. tariffs, boasting nine manufacturing facilities. This outlook reflects a strategic approach to the current tariff and trade landscape.
In terms of market performance, the stock for TEVA has surged by 18.23%, trading at approximately $24.19 at the last recorded check.
Frequently Asked Questions
What are the latest financial results for Teva Pharmaceutical Industries?
Teva reported a third-quarter total revenue of $4.48 billion, exceeding expectations and reflecting a 3% year-over-year increase.
Which drugs significantly contributed to Teva's revenue growth?
Key branded drugs such as Austedo, Ajovy, and Uzedy have driven significant revenue growth for Teva in the latest quarter.
What is the revenue outlook for Austedo in 2025?
The revenue outlook for Austedo has been raised to between $2.05 billion and $2.15 billion for the fiscal year.
How did Teva's stock perform recently?
Teva's stock rose by 18.23%, reaching a price of $24.19 in the latest market update.
What is Teva's earnings guidance for fiscal 2025?
Teva adjusted its fiscal year 2025 earnings range to $2.55 - $2.65, slightly above market expectations.
